🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT07405138
Starting soon Not applicable

Evaluation of Effectiveness and Safety of Intense Pulsed Light Treatment for Chalazion

NCT07405138 · tracked via the Priya Life Science USA tracker
Sponsor
Lumenis Be Ltd.
Phase
Not applicable
Started
2026-02-04
Last updated
2026-02-19

Condition(s) studied

Chalazion

Investigational drug(s) / intervention(s)

Sham IPLActive IPL

Sham IPL: Three sham IPL treatments in 1-week interval followed by 1 follow-up 4 weeks after the last treatment

Active IPL: Three active IPL treatments in 1-week interval followed by 1 follow-up 4 weeks after the last treatment

Study summary

To study the effectiveness and safety of IPL treatment for Chalazion

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: * Subject is able to read, understand, and sign an Informed Consent Form (ICF) * 18 years of age or older * Clinical diagnosis of chalazion in the inflammatory stage * Subject is willing to comply with all study procedures- Exclusion Criteria: * Concurrent eyelid infection * Chalazion with atypical features, which to the opinion of the study investigator is inadequate for a study * Recurring Chalazion * Floppy eyelid syndrome * Demodex blepharitis patients taking Lotilaner ophthalmic solution within 30 days prior to screening * Ocular surgery within 3 months prior to screening * Current diagnosis of malignant tumors in the affected eyelid, including: sebaceous carcinoma and basal cell carcinoma * Laser Assisted In Situ Keratomileusis (LASIK)/Small Incision Lenticule Extraction (SMILE) surgery, within 1 year prior to screening * Radial Keratotomy (RK) surgery * Recent ocular trauma, within 3 months prior to screening * Pre-cancerous lesions or skin cancer in the planned treatment area * Severe active allergies, or other severe uncontrolled eye disorders affecting the ocular surface * Uncontrolled infections or uncontrolled immunosuppressive diseases * Best corrected visual acuity worse than 20/200 in either eye * Ocular surface abnormality that may compromise corneal integrity in either eye (e.g., prior chemical burn, Epithelial Basement Membrane Dystrophy - EBMD) * Within 1 week prior to screening, use of photosensitive medication and/or herbs that may cause sensitivity to 560-1200 nm light exposure, including: Isotretinoin, Tetracycline, Doxycycline, and St. John's Wort * Active sun burn in the treatment area * Anterior chamber inflammation * Corneal edema * Any condition revealed w

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Manhattan Face and Eye clinic New York New York
Periman Eye Institute Seattle Washington

More Lumenis Be Ltd. trials in the USA

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07405138 on ClinicalTrials.gov ↗ ← All trials in the USA